Review Article
Clinicopathological and Prognostic Significance of CBX3 Expression in Human Cancer: a Systematic Review and Meta-analysis
Table 1
Characteristics of included studies in the meta-analysis.
| | Study | Year | Country | Cancer type | Case no. | Male/female | Detection method | Cutoff value | Increased CBX3 (%) | HR for OS (U) | HR for OS (M) | NOS. (scores) |
| | Zhong et al. | 2019 | China | HCC | 354 | 34/320 | IHC | Youden’s index | 196 (55.4%) | 1.37 | 1.38 | 9 | | Zhang et al. | 2018 | China | TSCC | 126 | 81/45 | IHC | | 77 (61.1%) | 2.97 | 2.46 | 9 | | Zhang et al. | 2018 | China | TSCC | 98 | 58/40 | IHC | | 42 (42.9%) | 3.56 | 2.97 | 8 | | Xu et al. | 2018 | China | CRC | 30 | 17/13 | IHC | | 15 (50.0%) | NA | NA | 9 | | Alam et al. | 2018 | America | LUAD | 73 | 13/60 | IHC | | 24 (32.8%) | 1.67 | NA | 8 | | Chang et al. | 2017 | China | PCa | 62 | 62/0 | IHC | Mean | 34 (54.8%) | 1.53 | 3.7 | 7 | | Zhu et al. | 2017 | China | RCC | 521 | NA | IHC | NA | 259 (49.7) | 1.48 | NA | 6 | | Liu et al. | 2015 | China | CRC | 178 | 104/74 | IHC | | 103 (61.2%) | 1.71 | NA | 9 | | Deng et al. | 2014 | China | BLCA | 62 | 12/50 | IHC | | 30 (48.4%) | 7.05 | 4.1 | 9 | | Zhou et al. | 2014 | China | NSCLC | 108 | 85/23 | IHC | | 30 (27.8%) | 1.66 | 2.13 | 9 | | Wang et al. | 2014 | China | CESC | 70 | 0/70 | IHC | | 42 (60.0%) | NA | NA | 7 |
|
|
Abbreviations: IHC: immunohistochemistry; OS: overall survival; NOS: Newcastle-Ottawa Scale; U: univariate analysis; M: multivariate analysis; NA: not available; HCC: hepatocellular carcinoma; TSCC: tongue squamous cell carcinoma; CRC: colorectal cancer; LUAD: lung adenocarcinoma; PCa: prostate cancer; RCC: renal carcinoma; BLCA: bladder urothelial carcinoma; NSCLC: non-small-cell lung cancer; CESC: cervical cancer. The HR values were extracted by the Engauge Digitizer 4.1 Software. |
